Tuberous Sclerosis Complex (TSC) neurons are neurons affected by mutations in the TSC1 or TSC2 genes, which lead to dysregulated mTOR (mechanistic target of rapamycin) signaling. TSC is a genetic disorder characterized by the development of benign tumors (hamartomas) in multiple organs, including the brain [1]. Neurological manifestations include epilepsy, intellectual disability, autism spectrum disorder, and tuberous sclerosis complex-associated neurodegeneration-like features. Understanding TSC neurons provides insight into mTOR function in the brain and has broader implications for other neurological conditions.
TSC is caused by mutations in two genes:
| Gene | Protein | Function |
|---|---|---|
| TSC1 | Hamartin | Tumor suppressor |
| TSC2 | Tuberin | GTPase-activating protein |
The TSC1/TSC2 complex acts as a guanosine triphosphatase-activating protein (GAP) for Rheb (Ras homolog enriched in brain), which is a direct activator of mTORC1 [2].
The mTOR pathway is a central regulator of cell growth:
mTOR Complex 1 (mTORC1):
Dysregulation in TSC:
TSC neurons exhibit characteristic abnormalities:
TSC neurons show altered firing properties:
Brain wiring is abnormal in TSC:
Epilepsy is the most common neurological manifestation in TSC:
Prevalence: 70-90% of TSC patients have epilepsy
Seizure Types:
Mechanisms:
Cognitive impairment varies widely:
30-50% of TSC patients meet criteria for ASD:
Recent research identifies neurodegeneration-like features:
Benign hamartomas in the cortex:
Tumors in the ventricles:
White matter abnormalities:
FDA-Approved:
Mechanism: Directly inhibit mTORC1, reversing hyperactivation [4]
Clinical Benefits:
Multiple drug classes used:
Curatolo, P., et al. (2015). Tuberous sclerosis complex. The Lancet Neurology, 14(7), 733-745 ↩︎
Huang, J., & Manning, B.D. (2008). The TSC1-TSC2 complex: a molecular signaling switch regulating growth, cell cycle, and metabolism. Journal of Cell Science, 121(Pt 2), 175-180 ↩︎
Rai, P., et al. (2019). The role of GABAergic signaling in the pathogenesis of tuberous sclerosis complex. Neuropharmacology, 155, 32-38 ↩︎
Franz, D.N., et al. (2013). Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the EXIST-1 trial. The Lancet Oncology, 14(9), 839-848 ↩︎